You are here: Industry Insights > Asthma

News List

Sanofi’s Dupixent reduces severe asthma attacks in children pharmatimes
October 15, 2020
Sanofi’s biologic therapy Dupixent (dupilumab) hit the mark in recently published data from a pivotal phase III trial.
US expands scope of Trelegy Ellipta to include asthma pharmatimes
September 24, 2020
GlaxoSmithKline and Innoviva's Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI) has bagged a new indication in the US with approval for use to treat asthma in patients aged 18 years.
GSK gets US FDA approval for Trelegy Ellipta to treat asthma, COPD expresspharma
September 18, 2020
Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.
High-dose Enerzair Breezhaler further cuts asthma exacerbations pharmatimes
September 08, 2020
A high dose of Novartis' Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate/IND/GLY/MF) significantly reduced asthma exacerbations compared to a medium dose, shows a new analysis.
Bilim Pharmaceuticals, H&T Presspart and Hovione Collaborate contractpharma
September 02, 2020
Bilim Pharmaceuticals, H&T Presspart and Hovione are collaborating to support Bilim Pharmaceutical’s launch into the Turkish market of Ventofor Combi Fix.
Study confirms link between SABA inhalers and asthma exacerbations pharmatimes
August 18, 2020
The UK’s largest asthma study using real-world data has confirmed a link between over-reliance on SABA inhalers (short-acting beta-2 bronchodilators, also referred to as rescue inhalers) and an increase in asthma exacerbations and asthma-related ...
Novartis banks EC approval for Enerzair Breezhaler pharmatimes
July 08, 2020
The European Commission (EC) has approved Novartis' Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate) for uncontrolled asthma.
MPs launch inquiry into UK asthma outcomes pharmatimes
June 17, 2020
The All-Party Parliamentary Group for Respiratory Health is launching an enquiry into asthma and severe asthma outcomes in the UK.
Lupin ties up with Omron Healthcare expresspharma
June 15, 2020
Medical device maker Omron Healthcare India has joined hands with pharma firm Lupin to strengthen respiratory disease management facilities, focussing on asthma and chronic obstructive pulmonary disease patients.
Trelegy Ellipta filing accepted by EMA for asthma pharmatimes
March 06, 2020
The European Medicines Agency (EMA) has accepted GlaxoSmithKline’s regulatory submission seeking an additional indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the treatment of asthma.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page